JP2021525517A5 - - Google Patents

Info

Publication number
JP2021525517A5
JP2021525517A5 JP2020566612A JP2020566612A JP2021525517A5 JP 2021525517 A5 JP2021525517 A5 JP 2021525517A5 JP 2020566612 A JP2020566612 A JP 2020566612A JP 2020566612 A JP2020566612 A JP 2020566612A JP 2021525517 A5 JP2021525517 A5 JP 2021525517A5
Authority
JP
Japan
Prior art keywords
lymphocytes
peptide
poly
dna molecule
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525517A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/064109 external-priority patent/WO2019229193A1/en
Publication of JP2021525517A publication Critical patent/JP2021525517A/ja
Publication of JP2021525517A5 publication Critical patent/JP2021525517A5/ja
Priority to JP2024034648A priority Critical patent/JP2024063211A/ja
Pending legal-status Critical Current

Links

JP2020566612A 2018-05-30 2019-05-29 内在性活性化誘導シチジンデアミナーゼを利用することによるbリンパ球のエンジニアリング Pending JP2021525517A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024034648A JP2024063211A (ja) 2018-05-30 2024-03-07 内在性活性化誘導シチジンデアミナーゼを利用することによるbリンパ球のエンジニアリング

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2018064299 2018-05-30
EPPCT/EP2018/064299 2018-05-30
PCT/EP2019/064109 WO2019229193A1 (en) 2018-05-30 2019-05-29 Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024034648A Division JP2024063211A (ja) 2018-05-30 2024-03-07 内在性活性化誘導シチジンデアミナーゼを利用することによるbリンパ球のエンジニアリング

Publications (2)

Publication Number Publication Date
JP2021525517A JP2021525517A (ja) 2021-09-27
JP2021525517A5 true JP2021525517A5 (cg-RX-API-DMAC7.html) 2022-05-31

Family

ID=62620827

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566612A Pending JP2021525517A (ja) 2018-05-30 2019-05-29 内在性活性化誘導シチジンデアミナーゼを利用することによるbリンパ球のエンジニアリング
JP2024034648A Pending JP2024063211A (ja) 2018-05-30 2024-03-07 内在性活性化誘導シチジンデアミナーゼを利用することによるbリンパ球のエンジニアリング

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024034648A Pending JP2024063211A (ja) 2018-05-30 2024-03-07 内在性活性化誘導シチジンデアミナーゼを利用することによるbリンパ球のエンジニアリング

Country Status (12)

Country Link
US (1) US20210254106A1 (cg-RX-API-DMAC7.html)
EP (1) EP3802841A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021525517A (cg-RX-API-DMAC7.html)
KR (1) KR20210016446A (cg-RX-API-DMAC7.html)
CN (1) CN112384627A (cg-RX-API-DMAC7.html)
AU (1) AU2019276261A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020024354A2 (cg-RX-API-DMAC7.html)
CA (1) CA3100112A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092807A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020012895A (cg-RX-API-DMAC7.html)
SG (1) SG11202011280SA (cg-RX-API-DMAC7.html)
WO (1) WO2019229193A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114181901B (zh) * 2021-12-08 2024-02-02 杭州中赢生物医疗科技有限公司 一种免疫细胞的体外诱导扩增和冻存的方法
US20250297288A1 (en) * 2022-05-10 2025-09-25 Editas Medicine, Inc. Genome editing of b cells
KR20250175332A (ko) * 2023-04-17 2025-12-16 비이 바이오파마, 인크. 혈우병 치료를 위한 조작된 세포 제제
CN117063890B (zh) * 2023-07-11 2025-12-05 吉林大学 一种heca基因不表达的异种移植供体猪及制备方法
WO2025147573A2 (en) * 2024-01-05 2025-07-10 Immusoft Corporation Glp-1 expressing modified b cells for the treatment of metabolic disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
PT841392E (pt) 1996-11-12 2004-11-30 Univ Auburn Vacina viva atenuada de neospora
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
AU2002953381A0 (en) * 2002-12-18 2003-01-09 Diatech Pty Ltd In vivo affinity maturation scheme
KR101121971B1 (ko) 2003-07-22 2012-03-09 비바리스 부착성 또는 비부착성 조류 세포주를 이용한폭스바이러스의 생산
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
WO2012063048A1 (en) * 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
US20130102031A1 (en) * 2011-10-25 2013-04-25 Anaptysbio, Inc. Use of somatic hypermutation to create insertion and deletion mutations in vitro
EP2927227A4 (en) 2013-01-03 2015-12-30 Celltrion Inc ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH
CA2981077A1 (en) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2016207402A1 (en) 2015-06-26 2016-12-29 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
AU2016317936A1 (en) * 2015-09-04 2018-03-08 Tocagen Inc. Recombinant vectors comprising 2A peptide
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION

Similar Documents

Publication Publication Date Title
KR102503130B1 (ko) 내인성 t 세포 수용체의 표적화된 대체
US11591381B2 (en) Gene-edited natural killer cells
AU2018226857B2 (en) Compositions and methods for immunotherapy
CN109844118B (zh) 经操纵的免疫调节因子以及由此改变的免疫力
WO2017070429A1 (en) Methods involving editing polynucleotides that encode t cell receptor
CA3022266A1 (en) Allele editing and applications thereof
JP2023552816A (ja) 細胞内のmhcクラスiiを低減する組成物及び方法
AU2019376903A1 (en) Anti-LIV1 immune cell cancer therapy
JP2023501617A (ja) Car-t細胞を製造する方法
US20230014010A1 (en) Engineered cells with improved protection from natural killer cell killing
KR20210092236A (ko) 항-ptk7 면역세포 암 치료법
KR20180018457A (ko) 조작된 면역조절요소 및 이에 의해 변형된 면역 활성
Hudecek et al. Minicircle-based engineering of chimeric antigen receptor (CAR) T cells
AU2020382219A1 (en) Manufacturing process for making T cells expressing chimeric antigen receptors
EP4676520A1 (en) Systems targeting psma and ca9
JP2025525437A (ja) 操作されたt細胞
US20250034558A1 (en) Compositions and methods for targeting, editing or modifying human genes
Arroyo-Olarte et al. Expanded Alternatives of CRISPR–Cas9 Applications in Immunotherapy of Colorectal Cancer: R. Arroyo-Olarte et al.
US20260071238A1 (en) Materials and processes for engineering hypoimmunogenicity
US20250197811A1 (en) Compositions and methods for generating cells with reduced immunogenicity
EP4627096A1 (en) Lipid particles with cofusogens and methods of producing and using the same
WO2025255308A1 (en) Cd8 co-receptor chimeric polypeptides in tcr cell therapy
Huang et al. Reprogramming endogenous NK circuits by highly efficient nonviral genome editing
EP4705456A1 (en) Compositions and methods for targeting, editing or modifying human genes
WO2026055342A1 (en) Synthetic pathway activators